Since RPN13 is over expressed in cancer [17], Kisselev has hypothesized that the covalent RA inhibitors block both ends of the proteasome, whereas in normal cells only one end is block and the other can utilize alternative ubiquitin receptors to maintain some proteasome function [14]. The gene discussed is ADRM1; the disease is cancer.